Table 4.

Cost-effectiveness of bisphosphonates for real-world and ideal persistence alternatives

Alternatives		No-treatment	Real-world persistence	Ideal persistence
Costs (Discounted)	Average per patients	€3,402	€3,110	€2,833
	Incremental	--	-€293*	-€277**
Costs (Undiscounted)	Average per patients	4,428 €	€3,979	€3,529
	Incremental	--	-€449*	-€450**
Fractured women	Proportion	0.671	0.600	0.491
	Incremental	--	-0.071†	-0.109††
ICER	Discounted	--	(Dominated) €4,110	(Dominated) €2,535
	Undiscounted	--	(Dominated) €6,310	(Dominated) €4,114
Premature deaths	Proportion	0.061	0.049	0.034
	Incremental	--	-0,012†	-0,015††
ICER	Discounted	--	(Dominated) €25,073	(Dominated) €18,442
	Undiscounted	--	(Dominated) €38,489	(Dominated) €29,932

* μc_{Real-world persistence}--μc_{No treatment}; ** μc_{Ideal persistence}--μc_{Real-world persistence}

^† μE_{Real-world persistence}--μE_{No treatment}; ^†† μE_{Ideal persistence}--μE_{Real-world persistence}